ACR: CMS rule on Medicare drug price negotiation could have ‘unintended consequences’

A proposed CMS rule codifying the Medicare Drug Price Negotiation Program could result in “unintended consequences” for physician practices and treatment access, according to a statement from the American College of Rheumatology.In its statement, addressed to CMS Administrator Mehmet Oz, MD, the ACR warned that the new round of Medicare drug price negotiations may